# Nuclide record neuroblastoma-high-risk (indication). Data CC BY-NC 4.0, attribute "Data from Nuclide (nuclide.cc)". Whole corpus: https://nuclide.cc/api/v1/nuclide.nt
@prefix schema: <https://schema.org/> .
@prefix nuclide: <https://nuclide.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://nuclide.cc/indications/neuroblastoma-high-risk/>
  a schema:MedicalCondition ;
  nuclide:kind "indication" ;
  schema:identifier "neuroblastoma-high-risk" ;
  schema:name "High-risk neuroblastoma"@en ;
  schema:alternateName "INRG high-risk neuroblastoma"@en, "Metastatic neuroblastoma"@en, "MYCN-amplified neuroblastoma"@en, "Stage 4 neuroblastoma"@en ;
  schema:description "High-risk neuroblastoma has spread widely in a child over 18 months old or carries extra copies of the MYCN gene. Treatment lasts about 18 months and uses every tool: chemotherapy, surgery, high-dose chemotherapy with stem cell rescue, radiotherapy, and the anti-GD2 antibody dinutuximab, which raised survival in ANBL0032; eflornithine, given afterwards, was approved in 2023 to lower relapse."@en ;
  schema:url <https://nuclide.cc/indications/neuroblastoma-high-risk/> ;
  schema:dateModified "2026-09-17"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Neuroblastoma> ;
  schema:citation <https://en.wikipedia.org/wiki/Neuroblastoma>, <https://www.cancer.gov/types/neuroblastoma/hp/neuroblastoma-treatment-pdq> ;
  nuclide:tag "subtype-page", "paediatric" ;
  nuclide:related <https://nuclide.cc/isotopes/f-18/>, <https://nuclide.cc/isotopes/i-131/> ;
  nuclide:technologies <https://nuclide.cc/technologies/mibg-theranostics/> ;
  nuclide:companies <https://nuclide.cc/companies/y-mabs/> ;
  nuclide:terms <https://nuclide.cc/terms/curie-siopen-score/> ;
  nuclide:pipeline <https://nuclide.cc/trials/anbl1531/>, <https://nuclide.cc/drugs/i131-mibg/>, <https://nuclide.cc/ideas/idea-mfbg-pet-replaces-mibg/>, <https://nuclide.cc/technologies/mibg-theranostics/> ;
  nuclide:standardOfCare <https://nuclide.cc/trials/anbl1531/>, <https://nuclide.cc/drugs/i131-mibg/>, <https://nuclide.cc/technologies/mibg-theranostics/>, <https://nuclide.cc/drugs/temozolomide/>, <https://nuclide.cc/drugs/i131-mibg/> .